AI development duo to advance drug-metabolising enzymes 

Optibrium and Lhasa, developers of software and artificial intelligence (AI) solutions for drug discovery and development, have published a peer-reviewed study, Predicting Regioselectivity of AO, CYP, FMO and UGT Metabolism Using Quantum Mechanical Simulations and Machine Learning, where the team combined existing experimental results, quantum mechanics and machine learning to build predictive models for drug metabolism.

Unexpected metabolism can cause the failure of many late-stage drug candidates, or even the withdrawal of approved drugs. It is therefore essential to predict metabolism for potential drug candidates.  

Current predictive models of metabolism usually target the human Cytochrome P450 (CYP) enzyme family, due to its well-characterised role in the metabolism of drug-like compounds. However, there is an increasing need to predict metabolism for other enzymes, such as human Aldehyde Oxidates (AOs), Flavin-containing Monooxygenases (FMOs), and Uridine 5’-diphosphoglucuronosyltransferases (UGTs). 

The study demonstrates novel predictive models for AO, FMO, and UGT metabolism, and extends the existing model for CYP metabolism to preclinical species. Expanding the portfolio of predictive models beyond CYPs will enable drug discovery scientists to determine a compound’s metabolic fate more accurately, helping to design better drugs and identify toxicity earlier in the project. In silico modelling for CYP in preclinical species can also reduce animal testing in toxicology studies, making trials quicker, less expensive, and more ethical. 

Dr Mario Öeren, Principal Scientist at Optibrium, said: “Combining quantum mechanical simulations and machine learning has allowed us to successfully expand predictive models of metabolism to new enzymes — a unique undertaking which addresses some of the key preclinical challenges of today. We are confident that this research’s demonstrated ability to predict metabolism across a broad range of different metabolic enzymes will provide an invaluable resource for scientists approaching drug discovery.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free